932372-99-1

Basic information

• Product Name: 2-BROMO-5-IODOPHENOL
• Synonyms: 2-BROMO-5-IODOPHENOL;2-Bromo-5-iodophenol 97%;2-Bromo-5-iodophenol97%
• CAS NO: 932372-99-1
• Molecular Formula: C₆H₄BrIO
• Molecular Weight: 298.91
• Mol File: 932372-99-1.mol

Chemical Properties

• Boiling Point: 285.054 °C at 760 mmHg
• Flash Point: 126.197 °C
• Appearance: /
• Density: 2.37 g/cm³
• Vapor Pressure: 0.002mmHg at 25°C
• Refractive Index: 1.7
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 7.58±0.10(Predicted)
• CAS DataBase Reference: 2-BROMO-5-IODOPHENOL(CAS DataBase Reference)
• NIST Chemistry Reference: 2-BROMO-5-IODOPHENOL(932372-99-1)
• EPA Substance Registry System: 2-BROMO-5-IODOPHENOL(932372-99-1)

Safety Data

• RIDADR: UN1759
• Hazardous Substances Data: 932372-99-1(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
2-Bromo-5-iodophenol is utilized as a key intermediate in organic synthesis for the creation of a variety of complex molecules. Its unique structure, featuring both bromine and iodine atoms, allows for versatile chemical reactions, making it a preferred choice for the development of new compounds with specific properties.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 2-Bromo-5-iodophenol serves as a building block for the synthesis of pharmaceutically relevant molecules. Its presence in the molecular structure can influence the pharmacokinetics and pharmacodynamics of the resulting compounds, contributing to the discovery of novel drugs with improved therapeutic profiles.
Used in Dye and Pigment Production:
2-Bromo-5-iodophenol is employed as a starting material in the production of dyes and pigments. Its chemical properties enable the creation of colorants with specific characteristics, such as stability, solubility, and color intensity, which are essential for various applications in textiles, plastics, and other industries.

InChI:InChI=1/C6H4BrIO/c7-5-2-1-4(8)3-6(5)9/h1-3,9H

Upstream product

• 755027-18-0 1-bromo-4-iodo-2-methoxybenzene 
• 88-74-4 2-nitro-aniline 
• 20691-72-9 4-iodo-2-nitroaniline 
• 111721-74-5 2-bromo-5-iodoaniline 

Downstream Products

• 755027-18-0 1-bromo-4-iodo-2-methoxybenzene 
• 43192-34-3 4-bromo-3-methoxybenzaldehyde 
• 932373-00-7 1-bromo-4-iodo-2-(methoxymethoxy)benzene 
• 1095422-54-0 benzyl 2-(2-bromo-5-iodophenoxy)ethylcarbamate 
• 1313809-06-1 C₃₈H₆₆OSi₂ 
• 1313809-07-2 C₃₅H₅₈OSi 
• 1313809-05-0 1-bromo-2-hexadecyloxy-4-iodobenzene 

Relevant articles and documents

HETEROCYCLIC AND HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE

The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. Formula (I). In particular, the present description relates to substituted bicyclic heterocyclic and heteroaryl compounds compounds of Formula (I), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.

HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE

The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. In particular, the present description relates to substituted bicyclic heteroaryl compounds of Formula (I), Formula (II), Formula (III), or Formula (IV), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.

HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE

The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. In particular, the present description relates to substituted benzothiazole compounds of Formula (I) or (II), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.

Preparation method of 2-bromo-5-iodophenol

The invention discloses an industrial preparation method of 2-bromo-5-iodophenol. According to the industrial preparation method of the 2-bromo-5-iodophenol, ortho-nitroaniline serves as an initial raw material, and the 2-bromo-5-iodophenol is synthesized by iodination, diazotization bromination, reduction and diazotization phenol hydroxylation four-step reaction. The 2-bromo-5-iodophenol obtainedin the process is blue solid with the purity of 97.5%, raw material conversion rate in each step reaches 100%, and the total yield of the whole process reaches 17%.

Nanopatterning by molecular polygons

Molecular polygons with three to six sides and binary mixtures thereof form long-range ordered patterns at the TCB/HOPG interface. This includes also the 2D crystallization of pentagons. The results provide an insight into how the symmetry of molecules is

PROCESS FOR THE PREPARATION OF GUANIDINO SUBSTITUTED BI-AND POLYPHENYLS THAT ARE SUITABLE AS SMALL MOLECULE CARRIERS

A process for the production of a compound of formula (I), or a pharmaceutically acceptable salt thereof, Formula (I) which process comprises:(a) coupling a compound of formula (II) to a compound of formula (III) to form a compound of formula (IV).

SULFONAMIDE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY

A sulfonamide derivative having DP receptor antagonistic activity; and a medicinal composition and a therapeutic agent for allergic diseases which each contains the compound as an active ingredient. The derivative is a compound represented by the general formula (II): (II) (wherein ring A is an aromatic carbocycle, etc.; ring B is a nitrogenous nonaromatic heterocycle, etc.; ring C is an aromatic carbocycle, etc.; R1 is carboxy, etc.; R2's each independently is halogeno, etc.; R3 is optionally substituted alkyloxy, etc.; R4's each independently is halogeno, etc.; R5's each independently is optionally substituted alkyl, etc.; M is sulfonyl, etc.; Y is a single bond, etc.; L1 is a single bond, etc.; L2 is a single bond, etc.; k is 0, 1, 2, 3, or 4; n is 0, 1, or 2; and q is 0, 1, 2, or 3, provided that, for example, a) when ring B is a 6-membered nitrogenous heterocycle containing one or two nitrogen atoms and ring C is a benzene ring, then k is not 0), a pharmaceutically acceptable salt of the compound, or a hydrate of either.

Halogen-lithium exchange between substituted dihalobenzenes and butyllithium: Application to the regioselective synthesis of functionalized bromobenzaldehydes

Halogen-lithium interconversion reactions between unsymmetrically substituted mono- and bifunctional dihalobenzenes C6H 3XHal2 and C6H2XYHal2 (Hal=Br, I; X, Y=F, OR, CF3, CH(OMe)2) and butyllithium were investigated. The resultant organolithium intermediates were converted into the corresponding benzaldehydes in moderate to good yields. As a rule, bromine atoms in the position ortho to the functional group were replaced preferentially with lithium. Intramolecular competition experiments with bifunctional systems revealed that fluorine is capable of activating the neighboring bromine atom more strongly than methoxy and dimethoxymethyl groups. On the replacement of the non-activated bromine with iodine a complete reversal of this reactivity pattern can be accomplished due to the preferred iodine-lithium exchange.